{
  "outcomes_metadata": {
    "timestamp": "2025-10-02T18:15:58.371541",
    "indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
    "consolidation_type": "outcomes",
    "data_split": "test",
    "total_unique_outcomes": 38,
    "source_countries": [
      "DE",
      "DK",
      "EN",
      "EU",
      "FR",
      "PT",
      "SE"
    ],
    "source_types": [
      "clinical_guideline",
      "hta_submission"
    ]
  },
  "consolidated_outcomes": {
    "efficacy": {
      "survival_endpoints": [
        "overall survival (OS)",
        "overall survival (time from randomisation to death from any cause)",
        "prolonged survival",
        "event-free survival",
        "eventless survival",
        "progression-free survival (PFS)",
        "progression-free survival (blinded, independent central review)",
        "progression-free survival (investigator-assessed)",
        "progression-free survival (RECIST)",
        "progression-free survival (independent, blinded review panel; RECIST 1.1)",
        "progression-free survival (measured by independent review committee; RECIST 1.1)",
        "progression-free survival (measured by RECIST 1.1)",
        "progression-free survival (measured by time to death)",
        "progression-free survival"
      ],
      "response_measures": [
        "objective response rate (ORR)",
        "objective response rate (RECIST 1.1)",
        "objective response rate (independent review committee; RECIST 1.1)",
        "overall response rate",
        "response rates",
        "disease control rate",
        "disease control rate (proportion with complete, partial, or stable disease for â‰¥5 weeks)",
        "duration of response (DoR)",
        "duration of response (RECIST 1.1)",
        "time to response (from treatment initiation to first complete or partial response)"
      ],
      "progression_measures": [
        "time to progression (TTP)",
        "time to progression",
        "progression after next line of therapy (PFS2)",
        "time to next treatment (TTNT)",
        "time to next treatment",
        "treatment duration",
        "duration of treatment"
      ]
    },
    "safety": {
      "adverse_events": [
        "adverse events",
        "adverse events (CTCAE v5.0)",
        "adverse events (CTCAE v4.03)",
        "adverse events (general)",
        "side effects",
        "serious side effects on the skin",
        "serious undesirable effects",
        "diarrhoea",
        "alanine aminotransferase increase",
        "aspartate aminotransferase increase",
        "neutropenia",
        "fatigue",
        "febrile neutropenia",
        "mortality-related toxicity"
      ],
      "serious_events": [
        "serious adverse events",
        "serious adverse events (Grade 3-4)"
      ],
      "discontinuations": [
        "dropout rate"
      ]
    },
    "quality_of_life": {
      "patient_reported_outcomes": [
        "EORTC QLQ-C30",
        "EORTC QLQ-LC13",
        "BPI-SF",
        "FACT-G GP5",
        "PGI-C",
        "EQ-5D-5L",
        "visual analogue scale"
      ],
      "functional_status": [
        "Karnofsky performance status",
        "ECOG performance status",
        "physical functioning"
      ],
      "symptom_measures": [
        "symptomatology",
        "symptom control",
        "preservation of quality of life",
        "health status",
        "overall health status",
        "health-related quality of life",
        "health-related quality of life measured by time to death",
        "quality of life"
      ]
    },
    "economic": {
      "cost_effectiveness": [
        "cost-effectiveness (cost per QALY achieved)"
      ],
      "utilities": [
        "quality-adjusted life years (QALYs)",
        "utility decrement per cycle of treatment",
        "treatment-related disutility for intravenous administration"
      ],
      "resource_utilization": []
    },
    "other": {
      "exploratory_endpoints": [],
      "biomarkers": []
    }
  }
}